Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02569476 · ClinicalTrials.gov registry record · Phase 1
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
NCT02569476 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 119 participants.
The verdict
NCT02569476, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
Study Summary
This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies.
Interventions
- DRUG Zanubrutinib
- DRUG Obinutuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2016-01-13 |
| Est. Completion | 2020-09-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02569476
The ClinicalTrials.gov registry entry for NCT02569476 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zanubrutinib is the first listed.
NCT02569476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02569476 about?
NCT02569476 is a clinical study titled "BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies". This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies.
What is the current status of trial NCT02569476?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2016-01-13. Estimated completion is 2020-09-02.
What interventions are being tested in trial NCT02569476?
The interventions under investigation include: Zanubrutinib (DRUG), Obinutuzumab (DRUG).
Who is sponsoring clinical trial NCT02569476?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.